The Brigham and Women's Hospital, Inc.

Abcuro, Inc.

Other

Kenneth Evan Thompson

Stefano V Gulla

Steven A Greenberg

Harold F Guerndt, Jr

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

Anti-KLRG1 antibodies

The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.

Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies

A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.

KLRG1 antagonist signaling therapy

Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies

A planting hole burning apparatus and method of forming a row of spaced planting holes through a plastic film positioned atop a seed growing bed. The apparatus includes ground engaging wheels which support a frame. A heat dispenser rotor is connected to the frame for rotation about an axis transverse to the direction of travel of the apparatus in use. The rotor is made to rotate at a speed proportional to the ground speed of the apparatus and such that a distal end of the rotor moves arcuately in very close proximity to the plastic film at the bottom of the arc. Gearing and rotor length are selected so that the arcuate speed of the distal end of the rotor during its rearward travel at the bottom portion of its swing is equal to the ground speed of the apparatus. Various means for heating one or more distal ends of the rotor for burning the planting holes through the plastic film while rotating in close proximity to the plastic film are provided.

Growing community of inventors

Arlington, MA, United States of America

Kenneth Evan Thompson